Ann Arbor, MI, United States

Aastrom Biosciences

www.aastrom.com
Ann Arbor, MI, United States
SEARCH FILTERS
Time filter
Source Type

The present invention provides a fluid exchange cell culture technique and tissue repair cells (TRCs) made by these methods, as well as methods using these cells. The method includes a new wash step which increases the tissue repair properties of the TRCs of the invention. This wash step allows for the production of TRC populations with greater tissue repair and anti-inflammatory capabilities. Embodiments of the present invention include a post-culture process for cultured cells that preferably includes the steps of: a wash process for removing unwanted residual culture components, a volume reduction process, and a harvesting process to remove cultured cells. Preferably, all these steps are performed within a aseptically closed cell culture chamber by implementing a separation method that minimizes mechanical disruption of the cells and is simple to automate. The harvested cells may then be concentrated to a final volume for the intended use. In such embodiments, the final composition is a substantially purified and concentrated cell mixture suspended in a physiologic solution suitable for immediate use in humans without further washing, volume reduction, or processing. Embodiments are also applicable to harvesting (and/or washing) particles within a liquid or solution within a chamber.


The present invention provides methods for treating critical limb ischemia (CLI), including increasing wound healing, decreasing wound size, increasing survival-free amputation, preventing amputation, preventing or delaying de novo gangrene, increasing survival probability, and preventing or delaying death, in subjects who prevent a vascular occlusion that cannot be resolved by using a standard method of revascularization, i.e. a subject with no-option CLI. Methods of the invention include administering to a subject with no-option CLI an isolated cell composition for tissue repair comprising a mixed population of cells of hematopoietic, mesenchymal and endothelial lineage, wherein the viability of said cells is at least 80% and the composition contains: a) about 5-75% viable CD90^(+) cells with the remaining cells in said composition being CD45^(+); b) less than 2 g/ml of bovine serum albumin; c) less than 1 g/ml of a enzymatically active harvest reagent; and d) substantially free of mycoplasma, endotoxin, and microbial contamination.


Patent
Aastrom Biosciences | Date: 2013-03-14

The present invention provides cell compositions and methods of using treating disorders, such as inflammatory disorders, such as atherosclerosis and cardiovascular disease.


Patent
Aastrom Biosciences | Date: 2012-05-18

The present invention provides compositions of mesenchymal stromal cells which express B7-H3, their subsequent use in tissue repair, improved methods of producing tissue repair cells and method of producing a substantially pure population of CD14+ autofluorescent macrophages.


Patent
Aastrom Biosciences | Date: 2013-03-11

The present invention relates to methods of generating an ex vivo tissue-like system in a bioreactor system capable of supporting continuous production of, and output of cells and tissues and an ex vivo tissue system made therefrom.


The present invention provides a fluid exchange cell culture technique and tissue repair cells (TRCs) made by these methods, as well as methods using these cells. The method includes a new wash step which increases the tissue repair properties of the TRCs of the invention. This wash step allows for the production of TRC populations with greater tissue repair and anti-inflammatory capabilities. Embodiments of the present invention include a post-culture process for cultured cells that preferably includes the steps of: a wash process for removing unwanted residual culture components, a volume reduction process, and a harvesting process to remove cultured cells. Preferably, all these steps are performed within a aseptically closed cell culture chamber by implementing a separation method that minimizes mechanical disruption of the cells and is simple to automate. The harvested cells may then be concentrated to a final volume for the intended use. In such embodiments, the final composition is a substantially purified and concentrated cell mixture suspended in a physiologic solution suitable for immediate use in humans without further washing, volume reduction, or processing. Embodiments are also applicable to harvesting (and/or washing) particles within a liquid or solution within a chamber.


The present invention provides a fluid exchange cell culture technique and tissue repair cells (TRCs) made by these methods, as well as methods using these cells. The method includes a new wash step which increases the tissue repair properties of the TRCs of the invention. This wash step allows for the production of TRC populations with greater tissue repair and anti-inflammatory capabilities. Embodiments of the present invention include a post-culture process for cultured cells that preferably includes the steps of: a wash process for removing unwanted residual culture components, a volume reduction process, and a harvesting process to remove cultured cells. Preferably, all these steps are performed within a aseptically closed cell culture chamber by implementing a separation method that minimizes mechanical disruption of the cells and is simple to automate. The harvested cells may then be concentrated to a final volume for the intended use. In such embodiments, the final composition is a substantially purified and concentrated cell mixture suspended in a physiologic solution suitable for immediate use in humans without further washing, volume reduction, or processing. Embodiments are also applicable to harvesting (and/or washing) particles within a liquid or solution within a chamber.


Patent
Aastrom Biosciences | Date: 2013-09-25

The present invention provides CD 14^(+ )cell compositions and methods of using same in treating disorders, such as inflammatory disorders, such as atherosclerosis and cardiovascular disease.


The present invention provides a method for processing cultured cells. The method includes the steps of providing a biochamber for culturing cells; providing a culture media for culturing cells within the biochamber; inoculating the biochamber with cells; culturing the cells; upon a predetermined time period of culture, displacing the culture media from the biochamber with a biocompatible first rinse solution; replacing the first rinse solution with a cell harvest enzyme solution; incubating the contents of the biochamber for a predetermined period of time, wherein during incubation, the enzyme at least dissociates the cells from each other and/or from the biochamber surface; and displacing the enzyme solution with a second rinse solution, wherein upon the enzyme being displaced, the chamber is substantially filled with the second rinse solution.


The present invention provides a method for processing cultured cells. The method includes the steps of providing a biochamber for culturing cells; providing a culture media for culturing cells within the biochamber; inoculating the biochamber with cells; culturing the cells; upon a predetermined time period of culture, displacing the culture media from the biochamber with a biocompatible first rinse solution; replacing the first rinse solution with a cell harvest enzyme solution; incubating the contents of the biochamber for a predetermined period of time, wherein during incubation, the enzyme at least dissociates the cells from each other and/or from the biochamber surface; and displacing the enzyme solution with a second rinse solution, wherein upon the enzyme being displaced, the chamber is substantially filled with the second rinse solution.

Loading Aastrom Biosciences collaborators
Loading Aastrom Biosciences collaborators